Related posts
Consumer, housing data misses, stocks sinkWall Street edges up, Tesla beats3 Best U.S. Healthcare ETFsThis summary was created by AI, based on 13 opinions in the last 12 months.
Experts are generally positive about Stryker Corp. (SYK-N), highlighting its strong position in the medical device market, its loyal customer base, and international growth opportunities. They also note the impact of the Covid-19 pandemic on the company's business and the potential for future acquisitions. While there are concerns about the stock's valuation and recent downtrend in the chart, overall confidence in the company's long-term prospects remains high.
Good products, good reputation. Good long-term investment in the medical device area. If you own it, keep holding. Her exposure to the space is via ABT and JNJ.
(Analysts’ price target is $379.00)73% of their business comes from the U.S. with the rest from Europe and emerging markets. They make great surgical products (i.e. hip replacements). Also, surgeons are loyal to SYK products and rarely change brand. Aging demographics and foreign markets offer growth.
Problem with the chart right now is it's making a lower high and a lower low. Looks like we just took out the last low. In the near term, that's a downtrend. He doesn't buy into downtrends or ride downhill rollercoasters. If it does decide to stop, reasonable chance that it will stop near old breakout point, ~$300. If it finds support and bounces off, could be a great time to buy.
Wonderful business, one of the best operators in healthcare. Balance sheet back to being clean and ready to make acquisitions. Expects extremely strong results. A leader, and gaining market share. Valuation is pricey, needs to deliver future gains, so stock's hit a wall. He's still buying, loves it long term.
(Analysts’ price target is $372.00)Sales machine. Market leader in joint replacement and medical products. Post-pandemic backlogs still huge. Double-digit topline revenue growth last few years, should continue. Acquisitive. Good free cashflow. Still growth in EMs. Valuation's run up, but he's not selling.
Has since sold shares. Believes stock is fully valued. Medical device business performing well. Surgeries recovered after pause during Covid-19 pandemic.
Demographic tailwind. User loyalty. Most revenue comes from US. Global growth opportunities, especially in EM. Medical devices are really changing how people live. Covid backlog is being caught up. Tuck-on acquisitions. Yield is 0.9%.
(Analysts’ price target is $360.04)Revenue: US (73%), developed world (19%), emerging markets (rest). Lots of good growth internationally. Demographic play. Strong brand loyalty. Free cash will be used for acquisitions. Great compounding story for the next several years. Yield is 0.9%.
(Analysts’ price target is $356.78)AI and weight-loss drugs are the two manias in the market now. SYK makes medical devices (hip and knee), but you must be below a certain weight to qualify for these operations. The weight-loss drugs will open a greater market for SYK.
Great story. Medical devices is a really important area of healthcare. Tremendous brand loyalty from end-user, plus a demographic play. Great operating margins and quarterly numbers, which will just keep on getting better. Lots of growth internationally. Yield is 0.9%.
(Analysts’ price target is $350.67)Medical devices are an important area that keeps people out of expensive hospitals, improves quality of life, and reduces reliance on drugs. Great advances, which will grow over the years. You want to be in this area. He owns SYK and JNJ in the space.
Medical devices. Joint replacements. Huge backlog due to Covid. Costs increased from supply chains and labour, but now sorted out. Really improves quality of life. Great business, lots of growth from aging demographics. Lots of growth internationally, too. Once a doctor "buys in", tremendous brand loyalty. Yield is 1%.
(Analysts’ price target is $318.71)It is in the medical devices field producing parts for artificial knees, hips, etc. and improving patient quality of life. Surgeons tend to stick with the same products so there is a stability to its income. The backlog from Covid is being decreased but there is room to grow internationally and an aging population needs more of these surgeries. 72% of its business comes from the U.S. and the rest from emerging markets and the developed world. They have lots of free cash flow to buy other companies. Buy 18 Hold 11 Sell 1
(Analysts’ price target is $314.49)Doing well given the backlog in surgeries. 73% of their business is in the US, but there's growth in emerging markets where they also operate. Doctors stick with their products and seldom change. Also, aging demographics help. They could make acquisitions, which will benefit them.
(Analysts’ price target is $311.03)Stryker Corp. is a American stock, trading under the symbol SYK-N on the New York Stock Exchange (SYK). It is usually referred to as NYSE:SYK or SYK-N
In the last year, 7 stock analysts published opinions about SYK-N. 6 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Stryker Corp..
Stryker Corp. was recommended as a Top Pick by on . Read the latest stock experts ratings for Stryker Corp..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
7 stock analysts on Stockchase covered Stryker Corp. In the last year. It is a trending stock that is worth watching.
On 2024-12-13, Stryker Corp. (SYK-N) stock closed at a price of $374.68.
Such an important area. Fell during Covid because classified as "elective" surgeries, but they aren't, as they help maintain quality of life without medication. Lots of opportunity to grow in EMs. Lots of free cashflow, which can be used for acquisitions.